Back to top
more

Avidity Biosciences (RNA)

(Delayed Data from NSDQ)

$41.87 USD

41.87
1,121,909

-0.39 (-0.92%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $41.88 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study

by Zacks Equity Research

Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes Avidity Biosciences, Inc. (RNA) a New Buy Stock

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Avidity Biosciences, Inc. (RNA) Could Rally 242%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Avidity Biosciences, Inc. (RNA) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 24.47% and 19.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -12.33% and 15.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Avidity Biosciences, Inc. (RNA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 9.09% and 73.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca Resumes Japan Study on Coronavirus Vaccine Candidate

by Zacks Equity Research

AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in Japan resume. The U.S. study remains on hold.